Literature DB >> 22237887

Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells.

Arthur A Hurwitz1, Stephanie K Watkins2.   

Abstract

Immune suppression remains a consistent obstacle to successful anti-tumor immune responses. As tumors develop, they create a microenvironment that not only supports tumor growth and metastasis but also reduces potential adaptive immunity to tumor antigens. Among the many components of this tumor microenvironment is a population of dendritic cells which exert profound immune suppressive effects on T cells. In this review, we discuss our recent findings related to these tumor-associated dendritic cells and how targeting them may serve to generate more durable anti-tumor immune responses.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22237887      PMCID: PMC6948839          DOI: 10.1007/s00262-011-1181-5

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  29 in total

1.  Regulation of NF-kappaB, Th activation, and autoinflammation by the forkhead transcription factor Foxo3a.

Authors:  Ling Lin; Jonathan D Hron; Stanford L Peng
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

Review 2.  Mast cells: multifaceted immune cells with diverse roles in health and disease.

Authors:  Kavitha N Rao; Melissa A Brown
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

Review 3.  Dendritic cells and tumor microenvironment: a dangerous liaison.

Authors:  Ingo Fricke; Dmitry I Gabrilovich
Journal:  Immunol Invest       Date:  2006       Impact factor: 3.657

4.  FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer.

Authors:  Stephanie K Watkins; Ziqiang Zhu; Elena Riboldi; Kim A Shafer-Weaver; Katherine E R Stagliano; Martha M Sklavos; Stefan Ambs; Hideo Yagita; Arthur A Hurwitz
Journal:  J Clin Invest       Date:  2011-03-23       Impact factor: 14.808

5.  Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells.

Authors:  M Aalamian; G Pirtskhalaishvili; A Nunez; C Esche; G V Shurin; E Huland; H Huland; M R Shurin
Journal:  Prostate       Date:  2001-01-01       Impact factor: 4.104

6.  Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers.

Authors:  Paola Pittoni; Claudio Tripodo; Silvia Piconese; Giorgio Mauri; Mariella Parenza; Alice Rigoni; Sabina Sangaletti; Mario P Colombo
Journal:  Cancer Res       Date:  2011-09-06       Impact factor: 12.701

7.  Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes.

Authors:  R Ganss; D Hanahan
Journal:  Cancer Res       Date:  1998-10-15       Impact factor: 12.701

8.  The TRAMP mouse as a model for prostate cancer.

Authors:  A A Hurwitz; B A Foster; J P Allison; N M Greenberg; E D Kwon
Journal:  Curr Protoc Immunol       Date:  2001-11

9.  Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Authors:  Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

10.  Immunosuppression induced by immature dendritic cells is mediated by TGF-beta/IL-10 double-positive CD4+ regulatory T cells.

Authors:  N Cools; V F I Van Tendeloo; E L J M Smits; M Lenjou; G Nijs; D R Van Bockstaele; Z N Berneman; P Ponsaerts
Journal:  J Cell Mol Med       Date:  2008-04       Impact factor: 5.310

View more
  35 in total

1.  A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapy.

Authors:  Brynn B Duncan; Steven L Highfill; Haiying Qin; Najat Bouchkouj; Shannon Larabee; Peng Zhao; Iwona Woznica; Yuxin Liu; Youhua Li; Wengen Wu; Jack H Lai; Barry Jones; Crystal L Mackall; William W Bachovchin; Terry J Fry
Journal:  J Immunother       Date:  2013-10       Impact factor: 4.456

2.  Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy.

Authors:  Karlo Perica; Joan Glick Bieler; Christian Schütz; Juan Carlos Varela; Jacqueline Douglass; Andrew Skora; Yen Ling Chiu; Mathias Oelke; Kenneth Kinzler; Shibin Zhou; Bert Vogelstein; Jonathan P Schneck
Journal:  ACS Nano       Date:  2015-07-14       Impact factor: 15.881

3.  Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy.

Authors:  Mads Hald Andersen
Journal:  J Natl Cancer Inst       Date:  2015-06-10       Impact factor: 13.506

4.  Origin and pharmacological modulation of tumor-associated regulatory dendritic cells.

Authors:  Hua Zhong; Dmitriy W Gutkin; Baohui Han; Yang Ma; Anton A Keskinov; Michael R Shurin; Galina V Shurin
Journal:  Int J Cancer       Date:  2014-01-20       Impact factor: 7.396

Review 5.  Combining radiotherapy and cancer immunotherapy: a paradigm shift.

Authors:  Silvia C Formenti; Sandra Demaria
Journal:  J Natl Cancer Inst       Date:  2013-01-04       Impact factor: 13.506

6.  Spontaneous presence of FOXO3-specific T cells in cancer patients.

Authors:  Stine Kiaer Larsen; Shamaila Munir Ahmad; Manja Idorn; Özcan Met; Evelina Martinenaite; Inge Marie Svane; Per Thor Straten; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2014-11-14       Impact factor: 8.110

7.  Splenectomy inhibits non-small cell lung cancer growth by modulating anti-tumor adaptive and innate immune response.

Authors:  Liran Levy; Inbal Mishalian; Rachel Bayuch; Lida Zolotarov; Janna Michaeli; Zvi G Fridlender
Journal:  Oncoimmunology       Date:  2015-01-22       Impact factor: 8.110

8.  Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation.

Authors:  C Andrew Stewart; Hannah Metheny; Noriho Iida; Loretta Smith; Miranda Hanson; Folkert Steinhagen; Robert M Leighty; Axel Roers; Christopher L Karp; Werner Müller; Giorgio Trinchieri
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

9.  Shaping of NK cell responses by the tumor microenvironment.

Authors:  Ana Stojanovic; Margareta P Correia; Adelheid Cerwenka
Journal:  Cancer Microenviron       Date:  2012-12-16

10.  Enterobacteriaceae bacteremias among cancer patients: an observational cohort study.

Authors:  Andrés F Henao-Martínez; Guido R González-Fontal; José R Castillo-Mancilla; Ivana V Yang
Journal:  Int J Infect Dis       Date:  2013-01-10       Impact factor: 3.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.